EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, MEI Pharma's enterprise value is $-27.13 Mil.
MEI Pharma's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $72.65 Mil. Therefore, MEI Pharma's EV-to-Revenue for today is -0.37.
The historical rank and industry rank for MEI Pharma's EV-to-Revenue or its related term are showing as below:
MEIP'
s EV-to-Revenue Range Over the Past 10 Years
Min: -7.76 Med: 3.86 Max: 106.28
Current: -0.37
During the past 13 years, the highest EV-to-Revenue of MEI Pharma was 106.28. The lowest was -7.76. And the median was 3.86.
MEIP's EV-to-Revenue is ranked better than 92.64% of 1033
companies
in the Biotechnology industry
Industry Median: 7.68
vs MEIP: -0.37
As of today (2024-04-27), MEI Pharma's stock price is $3.05.
MEI Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $10.90. Therefore, MEI Pharma's PS Ratio for today is 0.28.
MEI Pharma EV-to-Revenue Historical Data
The historical data trend for MEI Pharma's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of MEI Pharma's EV-to-Revenue
For the Biotechnology subindustry, MEI Pharma's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MEI Pharma's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MEI Pharma's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where MEI Pharma's EV-to-Revenue falls into.
MEI Pharma's current Enterprise Value is $-27.13 Mil.
MEI Pharma's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $72.65 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEI Pharma's share price for today is $3.05.
MEI Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $10.90.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEI Pharma EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of MEI Pharma's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MEIP has been successfully added to your 